Neurothrombectomy Devices Market Analysis

The stent retrievers segment was worth USD 378 million in 2023. Its ascendancy is attributed to their exceptional efficacy in treating ischemic stroke.

• Stent retrievers renowned for their high success rates in mechanically removing blood clots. These devices swiftly restore blood flow in affected vessels, leading to improved patient outcomes.
  
• Moreover, extensive clinical validation, versatility in addressing various clot sizes, and continuous technological advancements contribute to their dominance.
  
• Furthermore, medical guidelines endorsing stent retrievers as a standard of care, coupled with positive physician experiences and superior patient outcomes, solidifies their preference in the neurothrombectomy landscape.

Based on end-use, the hospitals and clinics segment garnered USD 463 million revenue in 2023.

• Hospitals and clinics take the lead in the neurothrombectomy devices market due to their centralized infrastructure, specialized expertise, and advanced imaging capabilities.
  
• These institutions provide a collaborative care environment, crucial for intricate neurothrombectomy procedures. Equipped with emergency services, post-procedure care infrastructure, and a commitment to regulatory standards, hospitals and clinics are well-positioned to address complex neurological conditions effectively.

U.S. neurothrombectomy devices market size surpassed USD 244 million in 2023 and is predicted to witness substantial market growth.

• The U.S. commands a leading position in the neurothrombectomy devices industry, stimulated by its advanced healthcare infrastructure, robust research and development landscape, and a high incidence of ischemic stroke.
  
• For instance, according to estimates from the Centers of Disease Control and Prevention, ischemic stroke accounts for around 87% of all strokes in the U.S., with 75% of cases occurring in individuals experiencing their first stroke. Annually, almost 800,000 Americans suffer from a stroke, ranking it as the fifth leading cause of death, with a mortality rate of 45.2 per 100,000 population.
  
• Thus, the country's strong emphasis on research and development, coupled with a high prevalence of ischemic strokes, fuels continuous advancements and widespread use of these devices.
  
• Furthermore, the presence of leading medical device manufacturers and a proactive approach to neurological healthcare further solidify the U.S.'s dominance in the market.